Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis
Precise prognosis is crucial for selection of adjuvant therapy in breast cancer. Molecular subtyping is increasingly used to complement immunohistochemical and pathological classification and to predict recurrence. This study compares both outcomes in a clinical setting. Molecular subtyping (MammaPr...
Main Authors: | José A. López-Ruiz, Jon A. Mieza, Ignacio Zabalza, María d. M. Vivanco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/17/4197 |
Similar Items
-
The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
by: Ettienne J. Myburgh, et al.
Published: (2021-10-01) -
Genetic and clinical landscape of ER + /PR- breast cancer in China
by: Danian Dai, et al.
Published: (2023-12-01) -
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
by: Bo Pan, et al.
Published: (2023-11-01) -
Genomic Assays in Node Positive Breast Cancer Patients: A Review
by: Maroun Bou Zerdan, et al.
Published: (2021-02-01) -
Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review
by: Maroun Bou Zerdan, et al.
Published: (2021-04-01)